Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo.
Antibodies, Monoclonal, Humanized
/ adverse effects
Chronic Disease
Dermatologic Agents
/ adverse effects
Female
Humans
Interleukin-4 Receptor alpha Subunit
/ therapeutic use
Male
Middle Aged
Patient Reported Outcome Measures
Prurigo
/ complications
Quality of Life
Retrospective Studies
Sleep Wake Disorders
/ etiology
atopic dermatitis
dupilumab
itch
nodular prurigo
Journal
Journal of the American Academy of Dermatology
ISSN: 1097-6787
Titre abrégé: J Am Acad Dermatol
Pays: United States
ID NLM: 7907132
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
09
10
2019
revised:
18
02
2020
accepted:
18
03
2020
pubmed:
2
4
2020
medline:
20
1
2021
entrez:
2
4
2020
Statut:
ppublish
Résumé
Chronic nodular prurigo (CNPG) is a multifactorial skin disease characterized by itchy papules and nodules, usually resistant to standard treatment and associated with markedly impaired quality of life. To describe dupilumab effectiveness and tolerability in treating adult patients with CNPG refractory to both topical and systemic therapies. Retrospective, multicenter study including adult patients affected by CNPG, who were treated with dupilumab for at least 16 weeks. Twenty-seven CNPG patients showed clinical improvement in terms of skin lesions, itch, sleeplessness, and quality of life. A consistent proportion of patients (24/27; 88.9%) had at least 16-week continuous treatment and achieved Investigator Global Assessment score 1 (11/24; 45.8%). An increased number of patients achieved at least a 2-grade reduction in Investigator Global Assessment score (19/24; 79.2%). Numeric rating scale values for itch and sleeplessness decreased from 8.9 to 2.7 and from 8.2 to 1.7, respectively (P < .001) after 16-week therapy. Ten patients achieved 36 weeks of continuous treatment while maintaining clinical efficacy. Major limitations included lack of validated assessment tools at the initial data collection, a limited cohort of treated patients, and a short-term observation period. Dupilumab was proven effective in reducing itch and improving CNPG skin lesions.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic nodular prurigo (CNPG) is a multifactorial skin disease characterized by itchy papules and nodules, usually resistant to standard treatment and associated with markedly impaired quality of life.
OBJECTIVE
OBJECTIVE
To describe dupilumab effectiveness and tolerability in treating adult patients with CNPG refractory to both topical and systemic therapies.
METHODS
METHODS
Retrospective, multicenter study including adult patients affected by CNPG, who were treated with dupilumab for at least 16 weeks.
RESULTS
RESULTS
Twenty-seven CNPG patients showed clinical improvement in terms of skin lesions, itch, sleeplessness, and quality of life. A consistent proportion of patients (24/27; 88.9%) had at least 16-week continuous treatment and achieved Investigator Global Assessment score 1 (11/24; 45.8%). An increased number of patients achieved at least a 2-grade reduction in Investigator Global Assessment score (19/24; 79.2%). Numeric rating scale values for itch and sleeplessness decreased from 8.9 to 2.7 and from 8.2 to 1.7, respectively (P < .001) after 16-week therapy. Ten patients achieved 36 weeks of continuous treatment while maintaining clinical efficacy.
LIMITATIONS
CONCLUSIONS
Major limitations included lack of validated assessment tools at the initial data collection, a limited cohort of treated patients, and a short-term observation period.
CONCLUSION
CONCLUSIONS
Dupilumab was proven effective in reducing itch and improving CNPG skin lesions.
Identifiants
pubmed: 32229281
pii: S0190-9622(20)30469-2
doi: 10.1016/j.jaad.2020.03.049
pii:
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Dermatologic Agents
0
Interleukin-4 Receptor alpha Subunit
0
dupilumab
420K487FSG
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
39-45Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.